Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.

Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML.

Vaccine. 2015 Aug 26;33(36):4548-53. doi: 10.1016/j.vaccine.2015.07.020.

PMID:
26209840
2.

Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?

Yang HC, Kao JH.

Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):129-31. doi: 10.1038/nrgastro.2015.8.

PMID:
25623202
3.

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G.

Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041.

Supplemental Content

Loading ...
Support Center